Holen Sie sich die Stockscreener-App
1.2498
5.82%
0.0598
Schlusskurs vom Vortag:
$1.19
Offen:
$1.18
24-Stunden-Volumen:
82,630
Relative Volume:
2.23
Marktkapitalisierung:
$26.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.16M
KGV:
-1.1903
EPS:
-1.05
Netto-Cashflow:
$-8.75M
1W Leistung:
+15.52%
1M Leistung:
+26.57%
6M Leistung:
-6.73%
1J Leistung:
+102.70%
1-Tages-Spanne:
$1.08
$1.2727
1-Wochen-Bereich:
$1.04
$1.2727
52-Wochen-Spanne:
$0.5306
$2.35
Renovorx Inc Stock (RNXT) Company Profile
Firmenname
Renovorx Inc
Sektor
Branche
Telefon
408-800-2649
Adresse
333 W. SANTA CLARA STREET, SUITE 900, SAN JOSE
Vergleichen Sie RNXT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| RNXT | 1.2592 | 26.88M | 0 | -9.16M | -8.75M | -1.05 |
| VRTX | 449.84 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.58 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.91 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.39 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
Eupraxia Pharmaceuticals Inc (EPRX-Q) QuotePress Release - The Globe and Mail
RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial - TipRanks
RenovoRx Expands Phase III Pancreatic Cancer Trial with Major Cancer Institute Partnership | RNXT Stock News - StockTitan
Peripheral IV Catheters Market: Rapid Global Data Volume Growth - openPR
RenovoRx reports Q3 net loss $2.5M vs $1.4M last year - TipRanks
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights - The Manila Times
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully - Simply Wall St
RenovoRx (NASDAQ:RNXT) Stock Price Up 2.5% – Still a Buy? - Defense World
RenovoRx ramps up production of RenovoCath system By Investing.com - Investing.com Australia
RenovoRx ramps up production of RenovoCath system - Investing.com
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians - GlobeNewswire
Rhumbline Advisers Has $1.23 Million Stock Holdings in The RMR Group Inc. (NASDAQ:RMR) - Defense World
Renovos Biologics Appoints New Non-Executive Director - European Pharmaceutical Manufacturer
RXO Inc (RXO) Shares Up 4.51% on Sep 19 - GuruFocus.com
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer - StockTitan
State of New Jersey Common Pension Fund D Has $2.48 Million Stock Position in RXO, Inc. (NYSE:RXO) - Defense World
Jefferies initates Ralph Lauren Corp (RL) stock to a Buy - Knox Daily
Reckitt shares up on report of potential homecare asset sale By Investing.com - Investing.com Australia
Reckitt starts talks on $7.9 bln homecare assets sale, Bloomberg News reports - XM
Federated Hermes Inc. Boosts Stock Position in The RMR Group Inc. (NASDAQ:RMR) - Defense World
Ascendiant Capital Markets Increases RenovoRx (NASDAQ:RNXT) Price Target to $8.25 - Defense World
RenovoRx (NASDAQ:RNXT) Trading Up 1.7% - Defense World
What was RenovoRx Inc (RNXT)’s performance in the last session? - US Post News
The time has not yet come to remove your chips from the table: RenovoRx Inc (RNXT) - SETE News
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York - StockTitan
RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024 - MSN
RenovoRx (NASDAQ:RNXT) Releases Quarterly Earnings Results - Defense World
RenovoRx continues drug-device combo Phase III trial in pancreatic cancer - Yahoo Finance
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - StockTitan
RenovoRx, Inc. - Stocks Telegraph
TAMP therapy shows promise in pancreatic cancer survival By Investing.com - Investing.com Nigeria
TAMP therapy shows promise in pancreatic cancer survival - Investing.com
RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist® - StockTitan
UNMC joins trial exploring new pancreatic cancer treatment - University of Nebraska Medical Center
Nektar Therapeutics (NASDAQ:NKTR) vs. RenovoRx (NASDAQ:RNXT) Critical Comparison - Defense World
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist® - StockTitan
RenovoRx Announces Publication Of Results Of Pre-Clinical Studies Support Efficacy And Drug Delivery Mechanism ... - Quantisnow
RenovoRx CEO Updates Shareholder Letter - Quantisnow
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC ... - StockTitan
RenovoRx Inc (RNXT) deserves closer scrutiny – US Post News - US Post News
RenovoRx (NASDAQ:RNXT) Coverage Initiated by Analysts at Ascendiant Capital Markets - Defense World
Ascendiant Capital highlights cancer therapy, sees potential on RenovoRx stock - Investing.com India
Ascendiant Capital highlights cancer therapy, sees potential on RenovoRx stock By Investing.com - Investing.com Australia
Analyzing Verrica Pharmaceuticals (NASDAQ:VRCA) and RenovoRx (NASDAQ:RNXT) - Defense World
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga
RenovoRx appoints new SVP to bolster strategy By Investing.com - Investing.com
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships - StockTitan
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships - GlobeNewswire Inc.
RenovoRx appoints new SVP to bolster strategy - Investing.com
RenovoRx announces $5M registered direct offering priced at-the-marketTipRanks.com - TipRanks
RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Up 28.9% in May - Defense World
Finanzdaten der Renovorx Inc-Aktie (RNXT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):